Literature DB >> 18251787

Palliative treatment of pancreatic cancer.

Götz von Wichert1, Thomas Seufferlein, Guido Adler.   

Abstract

Despite numerous diagnostic possibilities the early diagnosis of pancreatic cancer is still an exemption. Only 10-15% of patients are diagnosed at a stage where the tumor is resectable. Thus, most patients are treated with a palliative intention at first diagnosis. Palliative treatment comprises different therapeutic modalities involving radiochemotherapy and conventional chemotherapy. Chemotherapy, in particular, has been challenged by several new concepts involving combination regimens and the addition of targeted therapies to conventional therapeutic regimens. This review offers a critical presentation of current concepts in the palliative treatment of pancreatic cancer, discussing the problems of each and pointing to the development of new therapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18251787     DOI: 10.1111/j.1443-9573.2007.00314.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  10 in total

1.  Diagnosing and managing pancreatic cancer.

Authors:  Matthew T Huggett; Stephen P Pereira
Journal:  Practitioner       Date:  2011 Jul-Aug

2.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

3.  In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer.

Authors:  Clare Hoskins; Mehdi Ouaissi; Sofia Costa Lima; Woei Ping Cheng; Inês Loureirio; Eric Mas; Dominique Lombardo; Anabela Cordeiro-da-Silva; Ali Ouaissi; Paul Kong Thoo Lin
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

4.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.

Authors:  Wu Huanwen; Liang Zhiyong; Shi Xiaohua; Ren Xinyu; Wang Kai; Liu Tonghua
Journal:  Mol Cancer       Date:  2009-12-21       Impact factor: 27.401

5.  Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer.

Authors:  M T Huggett; M Jermyn; A Gillams; R Illing; S Mosse; M Novelli; E Kent; S G Bown; T Hasan; B W Pogue; S P Pereira
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

6.  Therapeutic Effects of Microbubbles Added to Combined High-Intensity Focused Ultrasound and Chemotherapy in a Pancreatic Cancer Xenograft Model.

Authors:  Mi Hye Yu; Jae Young Lee; Hae Ri Kim; Bo Ram Kim; Eun-Joo Park; Hoe Suk Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2016-08-23       Impact factor: 3.500

7.  Surgical bypass and permanent iodine-125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer.

Authors:  Zhenjiang Zheng; Yinglong Xu; Shu Zhang; Guangchun Pu; Chi Cui
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

8.  Tumor biology and cancer therapy - an evolving relationship.

Authors:  Thomas Seufferlein; Johann Ahn; Denis Krndija; Ulrike Lother; Guido Adler; Götz von Wichert
Journal:  Cell Commun Signal       Date:  2009-08-13       Impact factor: 5.712

9.  Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.

Authors:  Dao-Jun Gong; Jia-Min Zhang; Min Yu; Bo Zhuang; Qing-Qu Guo
Journal:  Clin Interv Aging       Date:  2013-07-16       Impact factor: 4.458

10.  A portable high-intensity focused ultrasound system for the pancreas with 3D electronic steering: a preclinical study in a swine model.

Authors:  Won Chang; Jae Young Lee; Jae Hwan Lee; Jae Seok Bae; Yeon Jin Cho; Kook Jin Kang; Keonho Son; Yul Ri Chung; Kyoung Bun Lee; Joon Koo Han
Journal:  Ultrasonography       Date:  2017-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.